Loading
Solange Peters is a lung cancer trialist and past ESMO President who led CheckMate 743 in mesothelioma.
Solange Peters is Head of Medical Oncology at Lausanne University Hospital (CHUV), working alongside the Ludwig Institute Lausanne, and served as President of the European Society for Medical Oncology (ESMO) in 2020-2021. Her specialisms are thoracic oncology, immunotherapy and mesothelioma. She led CheckMate 743, the Lancet trial of first-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma. Her work spans mesothelioma and non-small-cell lung cancer, and her publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743) | Lancet | 2021 |
Patients with KRAS G12C lung cancer that has progressed after chemo-immunotherapy can take an oral KRAS inhibitor instead of docetaxel and gain a somewhat longer time to progression with fewer severe side effects, but should understand that most tumours become resistant within a year and that survival is not improved. KRAS G12C testing is worthwhile, but first-generation inhibitors are a step rather than a cure; combinations and next-generation inhibitors are the active research fronts.
First-line ALK treatment moved to a drug designed for the brain, and brain metastasis prevention became an explicit design goal rather than a hoped-for side effect. ALK-positive lung cancer is now among the longest-surviving metastatic solid tumours.
Shares CheckMate 743, Mesothelioma, Ipilimumab, Nivolumab.
Shares CheckMate 743, Mesothelioma, Ipilimumab, Nivolumab.
Shares CheckMate 743, Ipilimumab, Nivolumab.
Shares ETOP IBCSG Partners Foundation, Mesothelioma, Non-small-cell lung cancer.
Shares ALEX, Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer, ALK-positive non-small-cell lung cancer, PD-L1-high non-small-cell lung cancer without a driver mutation.
Shares Mesothelioma, Ipilimumab, Nivolumab, Non-small-cell lung cancer.
Shares Mesothelioma, Ipilimumab, Nivolumab, Non-small-cell lung cancer.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Mesothelioma, Nivolumab, Non-small-cell lung cancer.